Namei Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Namei Wu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Feng Feng
Drilling Fluid Technology Service Center of Sinopec Shengli Petroleum Engineering Co., Ltd. Dongying China
1 shared publication - Honghui Guo
Department of Nutrition, School of Public Health Guangdong Medical University Zhanjiang China
1 shared publication - Shaohuang Weng
Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, China
1 shared publication - Shuifa Wu
Department of Pharmacy, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, China
1 shared publication - Shuquan Zhuang
Department of Pediatric, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, China
1 shared publication - Xiaofang Wang
Department of Pediatric, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, China
1 shared publication
Latest Publications
- Open Access
- 7 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (6) , e41426
Hypercalcemia in children with APL caused by interactions between voriconazole and all-trans retinoic acid: A case report and literature review
Rationale: All-trans retinoic acid (ATRA) and voriconazole (VRZ) are pivotal drugs for the treatment of acute promyelocytic leukemia (APL) and invasive fungal infections, respectively. When ATRA is co-administered with VRZ, clinically significant drug interactions may occur due to alterations in drug metabolism and clearance. Patient concerns: We report a case of hypercalcemia caused by the interaction between ATRA and VRZ in a child with APL. Diagnoses and interventions: A 14-year-old boy received arsenictrioxide (ATO) for APL and VRZ for invasive fungal infections, followed by planned maintenance therapy with ATRA monotherapy and combination of ATRA and ATO. He experienced no adverse reactions during the concurrent use of ATO and VRZ, while on the 12th day of combined ATRA and VRZ administration, his blood calcium levels significantly increased, accompanied by a series of symptoms. Following the discontinuation of VRZ and continuation of ATRA monotherapy, and subsequent maintenance chemotherapy with ATRA and ATO, his blood calcium levels decreased and remained within the normal range. Outcomes: We reviewed the published literature and excluded primary hyperparathyroidism or ectopic parathyroid hormone secretion as the cause of hypercalcemia in the child. He did not use other cytochrome inhibitors that may affect ATRA metabolism other than VRZ. Multiple measurements of VRZ trough concentrations ranged from 1.2 to 3 μg/mL. According to the Drug Interaction Probability Scale (5 points) and Naranjo Probability Scale (4 points), the drug interaction between VRZ and ATRA is probable. The hypercalcemia and other clinical manifestations may be caused by the inhibition of ATRA metabolism by VRZ. Lessons: During clinical use of ATRA, it is necessary to closely monitor the adverse drug interactions such as hypercalcemia and limit the use of drugs that may affect cytochrome P450 enzyme such as VRZ.
- 7 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (6) , e41426
Open AccessHypercalcemia in children with APL caused by interactions between voriconazole and all-trans retinoic acid: A case report and literature review
Rationale: All-trans retinoic acid (ATRA) and voriconazole (VRZ) are pivotal drugs for the treatment of acute promyelocytic leukemia (APL) and invasive fungal infections, respectively. When ATRA is co-administered with VRZ, clinically significant drug interactions may occur due to alterations in drug metabolism and clearance. Patient concerns: We report a case of hypercalcemia caused by the interaction between ATRA and VRZ in a child with APL. Diagnoses and interventions: A 14-year-old boy received arsenictrioxide (ATO) for APL and VRZ for invasive fungal infections, followed by planned maintenance therapy with ATRA monotherapy and combination of ATRA and ATO. He experienced no adverse reactions during the concurrent use of ATO and VRZ, while on the 12th day of combined ATRA and VRZ administration, his blood calcium levels significantly increased, accompanied by a series of symptoms. Following the discontinuation of VRZ and continuation of ATRA monotherapy, and subsequent maintenance chemotherapy with ATRA and ATO, his blood calcium levels decreased and remained within the normal range. Outcomes: We reviewed the published literature and excluded primary hyperparathyroidism or ectopic parathyroid hormone secretion as the cause of hypercalcemia in the child. He did not use other cytochrome inhibitors that may affect ATRA metabolism other than VRZ. Multiple measurements of VRZ trough concentrations ranged from 1.2 to 3 μg/mL. According to the Drug Interaction Probability Scale (5 points) and Naranjo Probability Scale (4 points), the drug interaction between VRZ and ATRA is probable. The hypercalcemia and other clinical manifestations may be caused by the inhibition of ATRA metabolism by VRZ. Lessons: During clinical use of ATRA, it is necessary to closely monitor the adverse drug interactions such as hypercalcemia and limit the use of drugs that may affect cytochrome P450 enzyme such as VRZ.
- 9 February 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (3) , 378-383
In Situ Growth of Plasmonic Gold Nanoparticles for the Direct and Sensitive Colorimetric Assay of Glucose
Gold nanoparticles (Au NPs)‐based colorimetric assay for the highly sensitive and selective detection of glucose has been conducted. The sensing, which was based on the in situ growth of Au NPs in the presence of glucose, was developed with the solution changing from colorless to red. This change could be observed with the naked eye or a ultraviolet–visible (UV–vis) spectrophotometer. Moreover, adding trace amounts of Tween‐20 kept Au NPs well spaced. Under the optimal assay conditions, the absorbance of Au NPs at 550 nm was proportional to glucose concentration within 400–1800 μM with a linear regression equation, and the detection limit was 6.28 μM. Some common interfering compounds in beverages, including other sugars, food additives, and amino acids, did not affect glucose sensing. Therefore, the proposed Au NP‐based colorimetric assay could be successfully used to determine glucose in beverages.
- 9 February 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (3) , 378-383
In Situ Growth of Plasmonic Gold Nanoparticles for the Direct and Sensitive Colorimetric Assay of Glucose
Gold nanoparticles (Au NPs)‐based colorimetric assay for the highly sensitive and selective detection of glucose has been conducted. The sensing, which was based on the in situ growth of Au NPs in the presence of glucose, was developed with the solution changing from colorless to red. This change could be observed with the naked eye or a ultraviolet–visible (UV–vis) spectrophotometer. Moreover, adding trace amounts of Tween‐20 kept Au NPs well spaced. Under the optimal assay conditions, the absorbance of Au NPs at 550 nm was proportional to glucose concentration within 400–1800 μM with a linear regression equation, and the detection limit was 6.28 μM. Some common interfering compounds in beverages, including other sugars, food additives, and amino acids, did not affect glucose sensing. Therefore, the proposed Au NP‐based colorimetric assay could be successfully used to determine glucose in beverages.